Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Eribulin mesylate is a nontaxane microtubule dynamics inhibitor approved for second-line (European Union) or third-line (United States) treatment of metastatic breast cancer. Two phase 2 single trials, evaluat...

Source: BMC Cancer - June 13, 2019 Category: Cancer & Oncology Authors: Lee Schwartzberg, Kristi McIntyre, Sharon Wilks, Shannon Puhalla, Joyce O ’Shaughnessy, Erhan Berrak, Yaohua He and Linda Vahdat Tags: Research article Source Type: research